A Study to Evaluate the Efficacy of CV-MG01 (Myasterix) in Myasthenia Gravis

Summary

Study CV-0003 will be the second clinical trial administering CV-MG01 in humans. This will be a phase 2/3 proof-of-efficacy therapeutic confirmatory study following the proof-of-concept exploratory phase 1 study (CV-0002).

Timeline

Start

2018-07

Primary completion

2019-10-01

Completion

2019-12-31

Outcome

Outcome not reported

Stopped (Enrollment): “Not enough participating centres to complete recruitment in a timely manner.”

Drugs

Indications